oxyphenbutazone

Trade name: Tandearil

Small moleculeapproved

Approved

Dec 21, 1960

Oxyphenbutazone is a non-steroidal anti-inflammatory drug, cyclooxygenase (prostaglandin synthetase) inhibitors which was marked under brand name tandearil for the treatment rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. But this drug was withdrawn from markets due to bone marrow suppression. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1960s

Dec 21, 1960
Novartis — Earliest FDA Approval
Dec 21, 1960
Novartis — NDA Secondary Org
Dec 21, 1960
Novartis — NDA Organization

Indications

Approved for

Inflammation (approved 1960)

Mechanism of action

CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
- Prostaglandin G/H synthase 2 (PTGS2) ↗
- Prostaglandin G/H synthase 1 (PTGS1) ↗
- Cyclooxygenase-1
- Cyclooxygenase-2

Approval history

approvedDec 21, 1960

Chemistry & pharmacology

Loading structure…

SMILES

CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O

Mol. weight: 342.4 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Oral

Oral

Yes

Parenteral

Topical

Sources

Also known as

butapirone
flamaril
oxazolidin
oxazolidin
oxazolidin
oxifenbutazona
oxifenbutazona
oxiphenbutazone
oxiphenbutazone
oxiphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazone
oxyphenbutazonum
oxyphenbutazonum
oxyphenobutazone
oxyphenylbutazone
p-oxyphenylbutazone
tandearil
tandearil
tandearil
tanderil
tanderil
tanderil chloramphen

Organizations

Marketing (3)

Organization	Org type	Relationship	Date
Novartis	For profit	NDA2	Dec 21, 1960
Novartis	For profit	NDA	Dec 21, 1960
Watson Pharmaceuticals	For profit	MKTG	—